Literature DB >> 11479427

Elevated procaspase levels in human melanoma.

D Fink1, H Schlagbauer-Wadl, E Selzer, T Lucas, K Wolff, H Pehamberger, H G Eichler, B Jansen.   

Abstract

In this study procaspase expression levels were investigated by Western blotting in a panel of established melanoma cell lines, transformed melanocytic cell lines and normal primary melanocytes. Upstream caspases such as procaspase-8 that contain a death effector domain were found to be overexpressed in transformed melanocytes and melanoma cell lines compared with melanocytes. Heterogeneous levels of procaspase-8 were seen in melanoma cells, including one cell line that completely lacked procaspase-8 expression. Procaspase-10 is generally overexpressed in transformed melanocytes and melanoma cell lines. Expression of the downstream procaspases-3 and -7 was increased in melanoma cells compared with normal melanocytes. Procaspases containing caspase recruitment domains such as procaspase-2 were expressed at similar levels in nearly all the cell lines investigated. Reduced levels of procaspase-1 compared with normal melanocytes were detected in transformed melanocytes and melanoma cell lines. These data indicate that procaspase levels in general increase during the malignant transformation of melanocytic cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479427     DOI: 10.1097/00008390-200108000-00009

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  20 in total

1.  Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1).

Authors:  Danny C Hsu; Howard S Roth; Diana C West; Rachel C Botham; Chris J Novotny; Steven C Schmid; Paul J Hergenrother
Journal:  ACS Comb Sci       Date:  2011-10-28       Impact factor: 3.784

2.  Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-beta-activated kinase 1.

Authors:  B Li; C C Smith; J M Laing; M D Gober; L Liu; L Aurelian
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

3.  Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells.

Authors:  Viralkumar Patel; Kumudha Balakrishnan; Michael J Keating; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2014-12-23       Impact factor: 22.113

4.  Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.

Authors:  Howard S Roth; Rachel C Botham; Steven C Schmid; Timothy M Fan; Levent Dirikolu; Paul J Hergenrother
Journal:  J Med Chem       Date:  2015-04-20       Impact factor: 7.446

5.  Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.

Authors:  Diana C West; Yan Qin; Quinn P Peterson; Diana L Thomas; Rahul Palchaudhuri; Karen C Morrison; Pamela W Lucas; Amy E Palmer; Timothy M Fan; Paul J Hergenrother
Journal:  Mol Pharm       Date:  2012-04-27       Impact factor: 4.939

6.  Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.

Authors:  Jessie Peh; Matthew W Boudreau; Hannah M Smith; Paul J Hergenrother
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

7.  PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition.

Authors:  Quinn P Peterson; David R Goode; Diana C West; Kara N Ramsey; Joy J Y Lee; Paul J Hergenrother
Journal:  J Mol Biol       Date:  2009-03-10       Impact factor: 5.469

8.  A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.

Authors:  Fangyang Wang; Lihui Wang; Yanfang Zhao; Yi Li; Guanfang Ping; Shu Xiao; Kang Chen; Wufu Zhu; Ping Gong; Jingyu Yang; Chunfu Wu
Journal:  Mol Oncol       Date:  2014-07-03       Impact factor: 6.603

9.  The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.

Authors:  Jessie Peh; Timothy M Fan; Kathryn L Wycislo; Howard S Roth; Paul J Hergenrother
Journal:  Mol Cancer Ther       Date:  2016-06-13       Impact factor: 6.261

10.  Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.

Authors:  Howard S Roth; Paul J Hergenrother
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.